S&CO Inc. Acquires 28,000 Shares of Travere Therapeutics, Inc. $TVTX

S&CO Inc. lifted its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 100.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 56,000 shares of the company’s stock after acquiring an additional 28,000 shares during the quarter. S&CO Inc.’s holdings in Travere Therapeutics were worth $1,338,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of TVTX. Stephens Investment Management Group LLC bought a new stake in Travere Therapeutics in the 3rd quarter valued at about $38,232,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Travere Therapeutics in the second quarter valued at approximately $14,831,000. Perceptive Advisors LLC bought a new stake in shares of Travere Therapeutics in the second quarter valued at approximately $12,347,000. Marshall Wace LLP bought a new position in Travere Therapeutics during the 2nd quarter worth $10,992,000. Finally, Cubist Systematic Strategies LLC bought a new position in Travere Therapeutics during the 2nd quarter worth $10,348,000.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Citigroup boosted their price target on Travere Therapeutics from $34.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Zacks Research cut shares of Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Piper Sandler increased their price objective on shares of Travere Therapeutics from $35.00 to $38.00 and gave the stock a “neutral” rating in a research note on Friday. Finally, Guggenheim restated a “buy” rating and issued a $49.00 target price on shares of Travere Therapeutics in a research report on Wednesday, January 14th. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $39.07.

Insider Activity at Travere Therapeutics

In related news, CEO Eric M. Dube sold 100,087 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $32.28, for a total transaction of $3,230,808.36. Following the completion of the transaction, the chief executive officer directly owned 432,886 shares in the company, valued at $13,973,560.08. This represents a 18.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christopher R. Cline sold 1,745 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $32.19, for a total transaction of $56,171.55. Following the completion of the transaction, the chief financial officer directly owned 111,226 shares of the company’s stock, valued at approximately $3,580,364.94. The trade was a 1.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 331,925 shares of company stock worth $11,318,755 in the last ninety days. Insiders own 4.06% of the company’s stock.

Travere Therapeutics Stock Performance

Travere Therapeutics stock opened at $30.07 on Tuesday. The company has a quick ratio of 2.71, a current ratio of 2.75 and a debt-to-equity ratio of 4.23. The stock has a market cap of $2.69 billion, a PE ratio of -28.37, a P/E/G ratio of 0.82 and a beta of 0.83. Travere Therapeutics, Inc. has a 12-month low of $12.91 and a 12-month high of $42.13. The business’s 50-day moving average price is $33.66 and its two-hundred day moving average price is $28.16.

Travere Therapeutics Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.